In Autumn 2020, DOAJ will be relaunching with a new website with updated functionality, improved search, and a simplified application form. More information is available on our blog. Our API is also changing.

Hide this message

Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder

Neuropsychiatric Disease and Treatment. 2017;Volume 13:437-441

 

Journal Homepage

Journal Title: Neuropsychiatric Disease and Treatment

ISSN: 1176-6328 (Print); 1178-2021 (Online)

Publisher: Dove Medical Press

LCC Subject Category: Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry: Neurology. Diseases of the nervous system

Country of publisher: United Kingdom

Language of fulltext: English

Full-text formats available: PDF, HTML

 

AUTHORS


Yoshimura R

Katsuki A

Atake K

Hori H

Igata R

Konishi Y

EDITORIAL INFORMATION

Blind peer review

Editorial Board

Instructions for authors

Time From Submission to Publication: 16 weeks

 

Abstract | Full Text

Reiji Yoshimura, Asuka Katsuki, Kiyokazu Atake, Hikaru Hori, Ryohei Igata, Yuki KonishiDepartment of Psychiatry, University of Occupational and Environmental Health, Yahatanishi-ku, Kitakyushu, Fukuoka, Japan Objectives: The etiology of depression remains unknown. There is, however, a growing body of evidence that cytokines are involved in the pathophysiology of depression. The aim of this study is to investigate the effects of fluvoxamine on plasma interleukin-6 (IL-6) levels and on clinical improvement of the depressive state.Subjects and methods: Thirty patients who met the DSM-IV criteria for major depressive disorder (MDD) were enrolled in the study. Thirteen were male and 17 were female, and their ages ranged from 26 to 70 years (mean ± standard deviation 45.0±14.2). The patients were treated with fluvoxamine for 8 weeks. The dosages of fluvoxamine varied among the patients and, based on ethical considerations, were not fixed.Results: The fluvoxamine doses were positively related to plasma fluvoxamine levels (r=0.8798, P<0.001). A significant correlation was observed between the patients’ plasma IL-6 levels and their 17-item Hamilton Rating Scale for Depression (HAMD17) scores (r=0.4555, P=0.0010). A positive correlation was found between the delta plasma IL-6 (week 0–week 8) and the delta HAMD17 (week 0–week 8) (r=0.5226, P=0.002).Conclusion: Effect of fluvoxamine on IL-6 is partially associated with its clinical efficacy for MDD. Keywords: fluvoxamine, interleukin, Hamilton Rating Scale for Depression, major depressive disorder